News

An RNAi-based approach to blocking the production of complement pathway factors offers the potential to inhibit the uncontrolled complement activation that leads to many diseases. The agreement provides

Xofluza is a first-in-class and single-dose oral medicine with a novel proposed mechanism of action, which restricts polymerase acidic endonuclease, an enzyme required for viral replication. According to

In the pharmaceutical industry, clinical-trial data is of paramount importance for drug development, and must be backed up and protected against any potential mishaps. Therefore, a Hybrid Cloud

The proceeds from the new funding round will be used by Stoke Therapeutics to advance its pipeline of antisense oligonucleotide medicines, designed for the treatment of severe genetic

Ci:z is engaged in the development, marketing and distribution of a range of dermocosmetic, cosmetic and skincare products. As per terms of the deal, J&J and its affiliates

Cerevel Therapeutics has secured $350m funding from funds affiliated with Bain Capital Private Equity and Bain Capital Life Sciences. They have also committed to provide further capital if

The partnership will enable CANbridge to develop and commercialize a portfolio of biotherapeutics for the treatment of rare diseases. This partnership leverages WuXi Biologics’ drug discovery, development and

The transaction combines two highly-complementary businesses and creates a medical cannabis industry innovator focused on the research and development of advanced cannabinoid treatments. Therapix Biosciences shareholders will receive

RPD designation for progeria and progeroid laminopathies enables priority review voucher (PRV) eligibility upon FDA approval of a rare pediatric disease product application for lonafarnib for these ultra-rare